From Medizone’s evaluation deal to Advantis Medical Imaging getting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Medizone inks AsepticSure evaluation deal with commercial cleaning products maker Innovasource Medizone announced in a March 22 press release that it has signed a product evaluation agreement with […]
Respiratory Motion said today it won CE Mark approval in the European Union for its ExSpiron non-invasive patient minute ventilation monitor. The ExSpiron patient monitor is designed to improve titration of opioids in postanesthesia care units and in general wards, and to alert attendants to respiratory depression in patientsadministered anesthetics during sedation cases, theWaltham, Mass.-based […]
Respiratory Motion is on a roll, landing nearly $6 million in new funding and unveiling positive results from a clinical study of its ExSpiron non-invasive respiratory monitor.
The Waltham, Mass.-based hopes to close the Series B round with $8.8 million, having raised $5.8 million so far from lead investor Easton Capital and other existing investors. The funds are slated to support sales and marketing efforts for the ExSpiron system, the company said.
According to Respiratory Motion CEO Dr. Jenny Freeman, breathing problems following surgery are highly under-reported, resulting more than 50,000 deaths per year. With a new FDA clearance in hand, Freeman said the company has several "irons in the fire" for its breath-monitoring device.
Massachusetts-based medical device maker Respiratory Motion won FDA approval for its ExSpiron respiratory monitoring system, the 1st monitor to provide continuous, noninvasive minute ventilation data to improve safely in non-ventilated patients.
Minute ventilation data, the amounts of air that enter and leave the lungs every minute, have not been previously available to doctors "across the continuum of care," according to the company.